These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36171144)

  • 21. Long-term improvement of metabolic control with pioglitazone in a woman with diabetes mellitus related to Dunnigan syndrome: a case report.
    Collet-Gaudillat C; Billon-Bancel A; Beressi JP
    Diabetes Metab; 2009 Apr; 35(2):151-4. PubMed ID: 19249234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A case of Dunnigan-type familial partial lipodystrophy (FPLD) due to lamin A/C (LMNA) mutations complicated by end-stage renal disease.
    Imachi H; Murao K; Ohtsuka S; Fujiwara M; Muraoka T; Hosokawa H; Ishida T
    Endocrine; 2009 Feb; 35(1):18-21. PubMed ID: 19011997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dunnigan-type familial partial lipodystrophy associated with the heterozygous R482W mutation in LMNA gene - case study of three women from one family.
    Nabrdalik K; Strózik A; Minkina-Pędras M; Jarosz-Chobot P; Młynarski W; Grzeszczak W; Gumprecht J
    Endokrynol Pol; 2013; 64(4):306-11. PubMed ID: 24002959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of KY-903, a Novel Tetrazole-Based Peroxisome Proliferator-Activated Receptor γ Modulator, in Male Diabetic Mice and Female Ovariectomized Rats.
    Ito Y; Yamamoto M; Furukawa S; Fukui M; Morishita K; Kitao T; Shirahase H
    Biol Pharm Bull; 2021; 44(5):659-668. PubMed ID: 33952822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study.
    Foss-Freitas MC; Akinci B; Neidert A; Bartlett VJ; Hurh E; Karwatowska-Prokopczuk E; Oral EA
    Lipids Health Dis; 2021 Dec; 20(1):174. PubMed ID: 34865644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical characteristics in two patients with partial lipodystrophy and Type A insulin resistance syndrome due to a novel heterozygous missense mutation in the insulin receptor gene.
    Iwanishi M; Kusakabe T; Azuma C; Tezuka Y; Yamamoto Y; Ito-Kobayashi J; Washiyama M; Morimoto M; Ebihara K
    Diabetes Res Clin Pract; 2019 Jun; 152():79-87. PubMed ID: 31102683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vascular placental abnormalities and newborn death in a pregnant diabetic woman with familial partial lipodystrophy type 3: a possible role for peroxisome proliferator-activated receptor γ.
    Castell AL; Hiéronimus S; Lascols O; Fournier T; Fénichel P
    Diabetes Metab; 2012 Oct; 38(4):367-9. PubMed ID: 22559930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Pharmacogenetic Approach to the Treatment of Patients With
    Agostini M; Schoenmakers E; Beig J; Fairall L; Szatmari I; Rajanayagam O; Muskett FW; Adams C; Marais AD; O'Rahilly S; Semple RK; Nagy L; Majithia AR; Schwabe JWR; Blom DJ; Murphy R; Chatterjee K; Savage DB
    Diabetes; 2018 Jun; 67(6):1086-1092. PubMed ID: 29622583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A single-base mutation in the peroxisome proliferator-activated receptor gamma4 promoter associated with altered in vitro expression and partial lipodystrophy.
    Al-Shali K; Cao H; Knoers N; Hermus AR; Tack CJ; Hegele RA
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5655-60. PubMed ID: 15531525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of Metreleptin Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants.
    Sekizkardes H; Cochran E; Malandrino N; Garg A; Brown RJ
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3068-3076. PubMed ID: 31194872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Leptin therapy for partial lipodystrophy linked to a PPAR-gamma mutation.
    Guettier JM; Park JY; Cochran EK; Poitou C; Basdevant A; Meier M; Clément K; Magré J; Gorden P
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):547-554. PubMed ID: 18076675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A case of familial partial lipodystrophy caused by a novel lamin A/C (LMNA) mutation in exon 1 (D47N).
    Kutbay NO; Yurekli BS; Onay H; Altay CT; Atik T; Hekimsoy Z; Saygili F; Akinci B
    Eur J Intern Med; 2016 Apr; 29():37-9. PubMed ID: 26775134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy.
    Hegele RA; Cao H; Frankowski C; Mathews ST; Leff T
    Diabetes; 2002 Dec; 51(12):3586-90. PubMed ID: 12453919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PPAR-γ-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH.
    Gastaldelli A; Sabatini S; Carli F; Gaggini M; Bril F; Belfort-DeAguiar R; Positano V; Barb D; Kadiyala S; Harrison S; Cusi K
    Liver Int; 2021 Nov; 41(11):2659-2670. PubMed ID: 34219361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C.
    Wong SP; Huda M; English P; Bargiota A; Wilding JP; Johnson A; Corrall R; Pinkney JH
    Diabetologia; 2005 Dec; 48(12):2641-9. PubMed ID: 16320084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Familial partial lipodystrophy and proteinuric renal disease due to a missense c.1045C > T
    Fountas A; Giotaki Z; Dounousi E; Liapis G; Bargiota A; Tsatsoulis A; Tigas S
    Endocrinol Diabetes Metab Case Rep; 2017; 2017():. PubMed ID: 28620495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Familial Partial Lipodystrophy-Literature Review and Report of a Novel Variant in
    Rutkowska L; Salachna D; Lewandowski K; Lewiński A; Gach A
    Diagnostics (Basel); 2022 Apr; 12(5):. PubMed ID: 35626278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pparg-P465L mutation worsens hyperglycemia in Ins2-Akita female mice via adipose-specific insulin resistance and storage dysfunction.
    Pendse AA; Johnson LA; Tsai YS; Maeda N
    Diabetes; 2010 Nov; 59(11):2890-7. PubMed ID: 20724579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A frameshift mutation in peroxisome-proliferator-activated receptor-gamma in familial partial lipodystrophy subtype 3 (FPLD3; MIM 604367).
    Hegele RA; Ur E; Ransom TP; Cao H
    Clin Genet; 2006 Oct; 70(4):360-2. PubMed ID: 16965332
    [No Abstract]   [Full Text] [Related]  

  • 40. Peroxisome proliferator-activated receptor gamma-ligand-binding domain mutations associated with familial partial lipodystrophy type 3 disrupt human trophoblast fusion and fibroblast migration.
    Shoaito H; Chauveau S; Gosseaume C; Bourguet W; Vigouroux C; Vatier C; Pienkowski C; Fournier T; Degrelle SA
    J Cell Mol Med; 2020 Jul; 24(13):7660-7669. PubMed ID: 32519441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.